dr. kelly stone, associate director of the division of pulmonology, allergy, and critical care in the fda’s centre for drug evaluation and research, noted in a news release that “some people, particularly children, may delay or avoid treatment due to fear of injections.”
because of this avoidance, many people are put at a heightened risk of worsened outcomes because delaying treatment while in anaphylaxis can mean the difference between life and death.
the data that led to the approval
to ensure the new nasal spray method would work as well for allergic reactions as it does for those with opioid overdoses, the drug was tested in both children and adults. when measured against injected epinephrine, the results showed that the nasal spray was as viable as the injection, giving researchers the data they needed to bring it to the fda for approval.
the data also showed that nasal spray offers the same results regarding seeking care following an anaphylaxis attack. both the epi-pen and other auto injectables, as well as the nasal spray, require a person to seek emergency care after an allergic reaction. because the spray is on an even keel with the injectable epinephrine, it is considered a secondary option for people who cannot handle needles.
contraindications and side effects
the only difference between the two appears to be the administration, which could cause issues for some people with nasal conditions. for example, someone living with nasal polyps or those who have had nasal surgery may not benefit from neffy since the absorption of the drug may not be sufficient.
both methods of epinephrine administration have side effects as well. the epipen may induce paleness, dizziness, weakness, headaches, anxiety, fear, and restlessness. in contrast, the nasal spray can cause a person to develop side effects such as throat irritation, tingling in the nose, headache, nasal discomfort, and feeling jittery.